Ventral Hernia Repair with a Hybrid Absorbable-Permanent Preperitoneal Mesh¹

Goldblatt et al.

DATA SUMMARY

- Patients: 148
- Robotic and open approach
- Preperitoneal placement
 - Underlay: 52.0%
 - Retromuscular: 43.9%

- 28 months median clinical follow-up
- 36 months median PRO follow-up
- 60 months maximum follow-up



QUALITY OUTCOMES

- Hernia recurrence: 0%
- Complete mesh removals: 2%
- Device-related adverse events (1 year): 0.7%
- Procedure-related SSI and SSO (30 days):

4.8%, 1.4%

- SSOPI (30 days): 2.7%
- SSOPI (1 year): 3.4%



PATIENT CHARACTERISTICS

- Mean BMI (kg/m²): 32
- Mean defect size: 88.2 cm²

Ventral Hernia Working Group Grade 2: 66%

Objective

To analyze device safety and clinical outcomes of ventral hernia repair with the GORE® SYNECOR Preperitoneal Biomaterial, a permanent high-strength mesh with bioabsorbable web scaffold technology.

Materials and Methods

Retrospective, multicenter, case review analyzed device/procedure endpoints and patient-reported outcomes (PRO) in patients treated for hernia repair with CDC Class 1 wounds.

Conclusions

Use of the GORE® SYNECOR Preperitoneal Biomaterial, which incorporates the proven advantages of both an absorbable synthetic mesh and the long-term durability of a permanent macroporous mesh, is safe and effective in complex ventral hernia repairs.

When used in the retromuscular space, the combination of these 2 materials had lower wound complications and recurrence rates than either type of material alone.



Reference

1. Gold End	latt MI, Reynolds M, Doerhoff CR, et al. Ventral hernia repair with a hybrid absorbable-permanent preperitoneal mesh. Surgical Laparoscopy, copy & Percutaneous Techniques. In press.	
i Co for eifu.gor	ult Instructions se nedical.com	
Refer t	Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and dications for the markets where this product is available. $R_{X \text{ only}}$	
Gore d	ices referenced within if any are used within their approved/cleared indications. Fore does not have knowledge of the indications and approval/	

Gore devices referenced within, if any, are used within their approved/cleared indications. Gore does not have knowledge of the indications and approval/clearance status of other medical products or surgical techniques. Gore makes no representation as to the other medical care determinations or actions that may be described in this article. The reader should contact respective manufacturer(s) for current and accurate information.

Products listed may not be available in all markets.

GORE, Together, improving life, SYNECOR and designs are trademarks of W. L. Gore & Associates.

© 2025 W. L. Gore & Associates, Inc. 24SS1010-EN01 JANUARY 2025

W. L. Gore & Associates, Inc. goremedical.com

